MedPath

AGENUS INC.

AGENUS INC. logo
πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

44

Active:14
Completed:14

Trial Phases

4 Phases

Phase 1:23
Phase 2:14
Phase 3:4
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (42 trials with phase data)β€’ Click on a phase to view related trials

Phase 1
23 (54.8%)
Phase 2
14 (33.3%)
Phase 3
4 (9.5%)
Not Applicable
1 (2.4%)

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Conditions
Colorectal Cancer (CRC)
Pancreatic Cancer
Non-Small Cell Lung Cancer (NSCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Sarcoma
Ovarian Cancer
Prostate Cancer
First Posted Date
2024-12-30
Last Posted Date
2024-12-30
Lead Sponsor
Agenus Inc.
Registration Number
NCT06751524

A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

Phase 2
Active, not recruiting
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
First Posted Date
2022-11-29
Last Posted Date
2025-02-17
Lead Sponsor
Agenus Inc.
Target Recruit Count
81
Registration Number
NCT05630183
Locations
πŸ‡ΊπŸ‡Έ

HonorHealth, Scottsdale, Arizona, United States

πŸ‡ΊπŸ‡Έ

USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

πŸ‡ΊπŸ‡Έ

USC Norris Oncology, Newport Beach, California, United States

and more 32 locations

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Phase 2
Active, not recruiting
Conditions
Metastatic Colorectal Cancer
Interventions
First Posted Date
2022-11-08
Last Posted Date
2025-09-04
Lead Sponsor
Agenus Inc.
Target Recruit Count
234
Registration Number
NCT05608044
Locations
πŸ‡ΊπŸ‡Έ

HonorHealth Research Institute, Scottsdale, Arizona, United States

πŸ‡ΊπŸ‡Έ

City of Hope National Medical Center, Duarte, California, United States

πŸ‡ΊπŸ‡Έ

Keck School of Medicine of the University of Southern California, Los Angeles, California, United States

and more 62 locations

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Conditions
Cancer
First Posted Date
2022-10-10
Last Posted Date
2025-04-30
Lead Sponsor
Agenus Inc.
Registration Number
NCT05572970
Locations
πŸ‡ΊπŸ‡Έ

University of Alabama at Birmingham, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

Arizona Oncology Associates, Tucson, Arizona, United States

πŸ‡ΊπŸ‡Έ

Hoag Gynecologic Oncology, Newport Beach, California, United States

and more 4 locations

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Phase 2
Active, not recruiting
Conditions
Advanced Melanoma
Interventions
First Posted Date
2022-09-07
Last Posted Date
2025-03-10
Lead Sponsor
Agenus Inc.
Target Recruit Count
174
Registration Number
NCT05529316
Locations
πŸ‡·πŸ‡Ί

Blokhin National Medical Research Oncology Centre, Moscow, Russian Federation

πŸ‡·πŸ‡Ί

Moscow City Oncology Hospital #62, Moscow, Russian Federation

πŸ‡ΊπŸ‡Έ

Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale, Arizona, United States

and more 48 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next

News

Breakthrough Immunotherapy Combination Shows Promise Against Common Colorectal Cancer in Phase 1 Trial

A phase 1 trial of 148 patients demonstrated that the combination of botensilimab and balstilimab immunotherapy drugs successfully treated microsatellite stable metastatic colorectal cancer, the most common form that has historically not responded to immunotherapy.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.